Nuvectis Pharma, Inc. (NVCT)
Develops cancer drugs targeting specific tumor-causing proteins in early testing stages.
$19.82+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+191.5%
The outlook
NVCT is trading above both its 50- and 200-day moving averages, positioning it in the upper half of its 52-week range. Analysts overwhelmingly favor the stock with a Strong Buy consensus, and their average price target sits roughly 60% above the current price. The overall data picture leans bullish based on technical positioning and analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 5 analysts
Price trendAbove its 50- & 200-day averages
52-week range60% of the way from its 52-week low to high
Price targetAvg target +60% vs current price
Analyst price target
~12-month · 5 analysts$31.80average target+60.4% vs now
Now $19.82
Low $22.00High $39.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$624.8M
52-wk high
$29.28
52-wk low
$5.55
50-day avg
$15.51
200-day avg
$9.80
Trailing P/E
—